1. Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes.
- Author
-
Martinov T, Swanson LA, Breed ER, Tucker CG, Dwyer AJ, Johnson JK, Mitchell JS, Sahli NL, Wilson JC, Singh LM, Hogquist KA, Spanier JA, and Fife BT
- Subjects
- Animals, B7-H1 Antigen immunology, Diabetes Mellitus, Experimental immunology, Female, Germinal Center immunology, Histocompatibility Antigens Class II immunology, Lymphocyte Activation immunology, Mice, Mice, Inbred NOD, Autoimmunity immunology, B-Lymphocytes immunology, CD4-Positive T-Lymphocytes immunology, Diabetes Mellitus, Type 1 immunology, Programmed Cell Death 1 Receptor immunology
- Abstract
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and although numerous patients respond, some develop autoimmune-like symptoms or overt autoimmunity characterized by autoantibody production. PD-1 inhibition accelerates autoimmunity in mice, but its role in regulating germinal centers (GC) is controversial. To address the role of PD-1 in the GC reaction in type 1 diabetes, we used tetramers to phenotype insulin-specific CD4
+ T and B cells in NOD mice. PD-1 or PD-L1 deficiency, and PD-1 but not PD-L2 blockade, unleashed insulin-specific T follicular helper CD4+ T cells and enhanced their survival. This was concomitant with an increase in GC B cells and augmented insulin autoantibody production. The effect of PD-1 blockade on the GC was reduced when mice were treated with a mAb targeting the insulin peptide:MHC class II complex. This work provides an explanation for autoimmune side effects following PD-1 pathway inhibition and suggests that targeting the self-peptide:MHC class II complex might limit autoimmunity arising from checkpoint blockade., (Copyright © 2019 by The American Association of Immunologists, Inc.)- Published
- 2019
- Full Text
- View/download PDF